OncLive® Clinical Updates: Cardiovascular Adverse Events with BTK Inhibitors in B Cell Malignancies
June-Wha Rhee, MD, discusses the benefit of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia, as well as the incidence of cardiac disorders associated with the BTK inhibitors.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
FDA Grants Priority Review to Perioperative Durvalumab Plus Neoadjuvant Enfortumab Vedotin in MIBC
3
Five Under 5: Top Oncology Videos for the Week of 9/20
4
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
5